This clinical trial is focused on studying the treatment of HIV, which stands for human immunodeficiency virus. The study compares two different medication regimens for managing HIV. One group of participants will receive Dovato, which contains the active substances lamivudine and dolutegravir sodium. The other group will receive Biktarvy, which includes emtricitabine, tenofovir alafenamide, and bictegravir (also known as GS-9883). The purpose of the study is to evaluate the effectiveness of these treatments in maintaining low levels of the virus in the body.

Participants in the study will be randomly assigned to one of the two treatment groups. The study will last for a total of 240 weeks, with regular check-ups and assessments at various intervals, such as weeks 48, 144, and 240. During these visits, blood samples will be collected to measure the amount of HIV in the blood and to assess the function of the immune system. The study will also monitor other health markers, including metabolic and cardiovascular health, to ensure the safety and effectiveness of the treatments.

The trial aims to demonstrate that the two-drug regimen of Dovato is not inferior to the three-drug regimen of Biktarvy in terms of controlling the virus. This means that the study will check if the simpler two-drug treatment is just as effective as the more complex three-drug treatment. Participants will be closely monitored throughout the study to ensure their well-being and to gather important data on the long-term management of HIV.